by Aya Gonzalez
Dec 03, 2020Vancouver-based firm Numinus announced yesterday it will collaborate with an arm of a longstanding non-profit association dedicated to the study of psychedelics in a first-of-its-kind clinical trial on MDMA.
Numinus has signed a collaboration agreement with the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of MAPS. Together they will seek approval to undertake a single-arm, open-label, compassionate access trial using MDMA-assisted psychotherapy for patients who are suffering from post-traumatic stress disorder (PTSD).
